



PATENT  
ST96042A

1653  
#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): ICARD-LIEPKALNS ET AL. EXAMINER: NOT ASSIGNED

SERIAL NO. : 09/595,947 ART UNIT : 1653

FILED : JUNE 16, 2000

FOR : POLYPEPTIDES OF THE "BASIC HELIX-LOOP-HELIX"  
BHLH FAMILY, CORRESPONDING NUCLEIC ACID  
SEQUENCES

RECEIVED  
SEP 24 2001  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on September 18, 2001.

William C. Coppola, Reg. No. 41,686  
(Name of Registered Representative)

Skafedra 9/18/01  
(Signature and Date)

INFORMATION DISCLOSURE STATEMENT UNDER  
37 C.F.R. 1.56, 1.97 AND 1.98

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication, or other information referred

to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b)(3), because it is being filed before the mailing of a first office action on the merits. However, if it is subsequently determined that this information disclosure statement has been filed after the mailing of a first office action, the Commissioner is hereby authorized to charge any fee due under 37 C.F.R. 1.17(P), or credit any overpayment, to account No. 18-1982.

Applicants concurrently submit herewith a PTO-1449 form and copies of references listed therein.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'W.C. Coppola', written over a horizontal line.

William C. Coppola  
Attorney for Applicants  
Registration No. 41,686

Aventis Pharmaceuticals Products Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4854



Approved for use through 09/30/98, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box ☐

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900


RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900

RECEIVED  
STEP 2  
Column  
Relevant  
Relevant  
Appear  
2001  
TECHNICAL 600/2900



Please type a plus sign (+) inside this box

1449A/PTO		U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	09/595,947
				Filing Date	JUNE 16, 2000
				First Named Inventor	ICARD-LIEPKA et al.
				Group Art Unit	1653
				Examiner Name	UNASSIGNED
Sheet	2	of	2	Attorney Docket Number	ST96042 A-US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, country, where published, source.	
	✓	Sommer et al., Neurogenins, A Novel Family of Atonal-Related bHLH Transcription Factors, And Putative Mammalian Neuronal Determination Genes That Reveal Progenitor Cell Heterogeneity In The Developing CNS and PNS, Mol. Cell Neurosci. 8(4), 221-241 (1996)	
	✓	Shimizu et al., MATH-2, A Mammalian Helix-Loop-Helix Factor Structurally Related To The Product Of Drosophila Proneural Gene Atonal, Is Specifically Expressed In The Nervous System, Eur. J. Biochem 229 (1), 239-248 (1995)	
	✓	Ravassard et al., Relax, A Novel Rat bHLH Transcriptional Regulator Transiently Expressed In The Ventricular Proliferating Zone Of The Developing Central Nervous System, J. Neurosci Res. 48(2), 146-158 (1997)	
	✓	Gradwohl, M. musculus MATH4B gene, EMBL databank (1996)	
	✓	Cau et al., Mash1 activates a cascade of bHLH regulators in olfactory neuron progenitors, Development 124, 1611-1621 (1997)	
	✓	Gradwohl, M. musculus MATH4C gene, GenBank Accession number Y09166	
		Ravassard, P., GenBank Accession number AJ133776 (Homo sapiens gene for neurogenin 3),	
		Ravassard, P. et al., GenBank Accession Number CAB45384 (Neurogenin 3 [Homo sapiens]),	

EXAMINER SIGNATURE

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.